Abstract
Multiple myeloma (MM) is an incurable plasma cell malignancy in which abnormal plasma cells accumulate in the bone marrow manifesting as osteolytic lesions in approximately 80% of the patients. Since bone disease is a hallmark of MM, sensitive imaging techniques directed at the detection of early bone lesions may be predictive of MM progression. Even though the current guideline for assessment of MM involves traditional skeletal survey, its limitations are well documented. However, several techniques have evolved in the preclinical cancer drug discovery including molecular and non-invasive imaging techniques, such as, low dose CT, molecularly targeted PET, MRI, single positron emission computed tomography, ultrasound and approaches like bioluminescence and fluorescence imaging. These techniques hold great promise in early diagnosis and monitoring of the disease and each has its share of advantages and disadvantages. An ideal technique should not alter the subject, should allow repeated measurements during the time course of the disease, should be sensitive enough to detect early disease and should have reasonably high specificity. However such technique is difficult to devise and test directly in human subjects due to technical challenges and ethical considerations and most of the pre-clinical research is done on the small animals.
This chapter will review some of the available molecular and conventional imaging techniques in multiple myeloma with emphasis on the combined use of MRI and FDG-PET scanning in murine model that can accurately monitor the extent and severity of MM, in real time both at molecular and cellular level. In the experience of the authors combining MRI and FDG-PET improves accuracy in screening and therapy related changes in myeloma. This approach can provide strategies that translate into the clinical paradigm and help to understand the biology of myeloma.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- FDG-PET:
-
18F–Fluorodeoxyglucose-positron emission tomography
- ASCT:
-
Autologous stem cell transplantation
- BLI:
-
Bioluminescence imaging
- CAR-T:
-
Chimeric antigen receptor-T
- CT:
-
Computed tomography
- DCE-MRI:
-
Dynamic contrast-enhanced MRI
- ELISA:
-
Enzyme-linked immunosorbent assay
- Exp-NK:
-
Expanded natural killer
- hIg:
-
Human immunoglobulins
- iNKT:
-
Invariant natural killer T cells
- MRI:
-
Magnetic resonance imaging
- MGUS:
-
Monoclonal gammopathy of undetermined significance
- MM:
-
Multiple myeloma
- NOD/SCID/IL2Rγnull-Hu:
-
Non-obese diabetic-SCID-IL2 receptor gamma null-human
- PET:
-
Positron emission tomography
- SCID:
-
Severe-combined immunodeficiency
References
Yaccoby S, Barlogie B, Epstein J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood. 1998;92:2908–13.
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–48.
Dammacco F, Rubini G, Ferrari C, Vacca A, Racanelli V. (1)(8)F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders. Clin Exp Med. 2015;15:1–18.
Genadieva-Stavric S, Cavallo F, Palumbo A. New approaches to management of multiple myeloma. Curr Treat Options Oncol. 2014;15:157–70.
van Frits R, Giralt S, Barlogie B. The future of autologous stem cell transplantation in myeloma. Blood. 2014;124:328–33.
Ayed AO, Chang LJ, Moreb JS. Immunotherapy for multiple myeloma: current status and future directions. Crit Rev Oncol Hematol. 2015;96:399–412.
Rotolo A, Caputo V, Karadimitris A. The prospects and promise of chimeric antigen receptor immunotherapy in multiple myeloma. Br J Haematol. 2016;173:350–64.
Baur-Melnyk A, Buhmann S, Becker C, Schoenberg SO, Lang N, Bartl R, et al. Whole-body MRI versus whole-body MDCT for staging of multiple myeloma. AJR Am J Roentgenol. 2008;190:1097–104.
Lutje S, de Rooy JW, Croockewit S, Koedam E, Oyen WJ, Raymakers RA. Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma. Ann Hematol. 2009;88:1161–8.
de Jong M, Maina T. Of mice and humans: are they the same?--Implications in cancer translational research. J Nucl Med. 2010;51:501–4.
Liao CP, Zhong C, Saribekyan G, Bading J, Park R, Conti PS, et al. Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. Cancer Res. 2007;67:7525–33.
Suggitt M, Bibby MC. 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin Cancer Res. 2005;11:971–81.
Zhang GJ, Chen TB, Bednar B, Connolly BM, Hargreaves R, Sur C, et al. Optical imaging of tumor cells in hollow fibers: evaluation of the antitumor activities of anticancer drugs and target validation. Neoplasia. 2007;9:652–61.
Cai W, Rao J, Gambhir SS, Chen X. How molecular imaging is speeding up antiangiogenic drug development. Mol Cancer Ther. 2006;5:2624–33.
Sanchez E, Chen H, Berenson JR. In vivo models of multiple myeloma (MM). Biochem Pharmacol. 2014;89:313–20.
Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat Rev Immunol. 2007;7:118–30.
Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842–54.
Garg TK, Szmania SM, Khan JA, Hoering A, Malbrough PA, Moreno-Bost A, et al. Highly activated and expanded natural killer cells for multiple myeloma immunotherapy. Haematologica. 2012;97:1348–56.
Gould SJ, Subramani S. Firefly luciferase as a tool in molecular and cell biology. Anal Biochem. 1988;175:5–13.
Moriyama EH, Niedre MJ, Jarvi MT, Mocanu JD, Moriyama Y, Subarsky P, et al. The influence of hypoxia on bioluminescence in luciferase-transfected gliosarcoma tumor cells in vitro. Photochem Photobiol Sci. 2008;7:675–80.
Tiffen JC, Bailey CG, Ng C, Rasko JE, Holst J. Luciferase expression and bioluminescence does not affect tumor cell growth in vitro or in vivo. Mol Cancer. 2010;9:299.
Troy T, Jekic-McMullen D, Sambucetti L, Rice B. Quantitative comparison of the sensitivity of detection of fluorescent and bioluminescent reporters in animal models. Mol Imaging. 2004;3:9–23.
O'Farrell AC, Shnyder SD, Marston G, Coletta PL, Gill JH. Non-invasive molecular imaging for preclinical cancer therapeutic development. Br J Pharmacol. 2013;169:719–35.
Dickson PV, Hamner B, Ng CY, Hall MM, Zhou J, Hargrove PW, et al. In vivo bioluminescence imaging for early detection and monitoring of disease progression in a murine model of neuroblastoma. J Pediatr Surg. 2007;42:1172–9.
Jurczok A, Fornara P, Soling A. Bioluminescence imaging to monitor bladder cancer cell adhesion in vivo: a new approach to optimize a syngeneic, orthotopic, murine bladder cancer model. BJU Int. 2008;101:120–4.
Nogawa M, Yuasa T, Kimura S, Kuroda J, Sato K, Segawa H, et al. Monitoring luciferase-labeled cancer cell growth and metastasis in different in vivo models. Cancer Lett. 2005;217:243–53.
Fomchenko EI, Holland EC. Mouse models of brain tumors and their applications in preclinical trials. Clin Cancer Res. 2006;12:5288–97.
Czernin J, Weber WA, Herschman HR. Molecular imaging in the development of cancer therapeutics. Annu Rev Med. 2006;57:99–118.
Hasegawa S, Furukawa T, Saga T. Molecular MR imaging of cancer gene therapy: ferritin transgene reporter takes the stage. Magn Reson Med Sci. 2010;9:37–47.
Kassouf W, Brown GA, Shetty A, Hazle JD, Stafford RJ, Rosser CJ, et al. An in vivo orthotopic canine model to evaluate distribution of intraprostatic injectate: implications for gene therapy and drug delivery for prostate cancer. Urology. 2007;70:822–5.
Breton E, Goetz C, Kintz J, Accart N, Aubertin G, Grellier B, et al. In vivo preclinical low-field MRI monitoring of tumor growth following a suicide-gene therapy in an orthotopic mice model of human glioblastoma. C R Biol. 2010;333:220–5.
Durie BG. The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. Eur J Cancer. 2006;42:1539–43.
Lyons SK. Advances in imaging mouse tumour models in vivo. J Pathol. 2005;205:194–205.
Nanni C, Zamagni E, Farsad M, Castellucci P, Tosi P, Cangini D, et al. Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. Eur J Nucl Med Mol Imaging. 2006;33:525–31.
Grange C, Geninatti-Crich S, Esposito G, Alberti D, Tei L, Bussolati B, et al. Combined delivery and magnetic resonance imaging of neural cell adhesion molecule-targeted doxorubicin-containing liposomes in experimentally induced Kaposi’s sarcoma. Cancer Res. 2010;70:2180–90.
Strijkers GJ, Kluza E, Van Tilborg GA, van der Schaft DW, Griffioen AW, Mulder WJ, et al. Paramagnetic and fluorescent liposomes for target-specific imaging and therapy of tumor angiogenesis. Angiogenesis. 2010;13:161–73.
Zaidi H, Prasad R. Advances in multimodality molecular imaging. J Med Phys. 2009;34:122–8.
Vansteenkiste JF. Imaging in lung cancer: positron emission tomography scan. Eur Respir J Suppl. 2002;35:49s–60s.
Otsuka H, Morita N, Yamashita K, Nishitani H. FDG-PET/CT for cancer management. J Med Invest. 2007;54:195–9.
Bredella MA, Steinbach L, Caputo G, Segall G, Hawkins R. Value of FDG PET in the assessment of patients with multiple myeloma. AJR Am J Roentgenol. 2005;184:1199–204.
Zamagni E, Cavo M. The role of imaging techniques in the management of multiple myeloma. Br J Haematol. 2012;159:499–513.
Avril N, Propper D. Functional PET imaging in cancer drug development. Future Oncol. 2007;3:215–28.
Laforest R, Liu X. Image quality with non-standard nuclides in PET. Q J Nucl Med Mol Imaging. 2008;52:151–8.
Cejka D, Kuntner C, Preusser M, Fritzer-Szekeres M, Fueger BJ, Strommer S, et al. FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo. Br J Cancer. 2009;100:1739–45.
Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. 2007;25:4714–21.
Diaz R, Nguewa PA, Parrondo R, Perez-Stable C, Manrique I, Redrado M, et al. Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model. BMC Cancer. 2010;10:188.
Kim TJ, Ravoori M, Landen CN, Kamat AA, Han LY, Lu C, et al. Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. Cancer Res. 2007;67:9337–45.
Leyton J, Alao JP, Da CM, Stavropoulou AV, Latigo JR, Perumal M, et al. In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. Cancer Res. 2006;66:7621–9.
Pollok KE, Lahn M, Enas N, McNulty A, Graff J, Cai S, et al. In vivo measurements of tumor metabolism and growth after administration of enzastaurin using small animal FDG positron emission tomography. J Oncol. 2009;2009:596560.
Cook GJ, Wegner EA, Fogelman I. Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging. Semin Nucl Med. 2004;34:122–33.
Acknowledgements
This work was funded by Medical Research Endowment Fund, University of Arkansas for Medical Sciences. We acknowledge support from Dr. M.J. Borrelli and technical assistance from A. Terri. We would like to thank A. Greenway and J.K. Khan for animal handling support.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Garg, T.K., Pandey, T. (2017). Simultaneous MRI and 18F-FDG-PET Imaging in Multiple Myeloma: A Model for Evaluation of the Disease and Therapeutic Changes in SCID-hu Mice. In: Pandey, T. (eds) Imaging in Stem Cell Transplant and Cell-based Therapy. Stem Cell Biology and Regenerative Medicine. Humana Press, Cham. https://doi.org/10.1007/978-3-319-51833-6_6
Download citation
DOI: https://doi.org/10.1007/978-3-319-51833-6_6
Published:
Publisher Name: Humana Press, Cham
Print ISBN: 978-3-319-51831-2
Online ISBN: 978-3-319-51833-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)